The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(3) and 4(c) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoters Sanjiv Goyal, Sanjiv (HUF) and Raman Goyal filed a SEBI disclosure under Regulation 10(7) reporting an increase in their voting rights following Nectar Lifesciences' recent share buyback. The company bought back 3 crore equity shares (13.38% of total) at Rs 27 per share between December 31, 2025 and January 6, 2026, for a total outflow of up to Rs 81 crore. Promoters did not tender any shares, so their absolute holdings stayed the same but their percentage stake rose from 44.91% to 51.84%, crossing the 50% mark. The increase is exempted under Regulation 10(3) and 10(4)(c) of the SEBI Takeover Regulations.
Promoter holding has crossed 50% (now 51.84%) purely because the public float shrank via buyback, not because promoters spent any money. This is a passive increase and is SEBI-exempt, but it reduces public shareholding to about 48.16% and concentrates ownership, which could affect liquidity and float on the exchanges.